Glycine toxicity after high-dose i.v. infusion of 1.5% glycine in the mouse

被引:28
|
作者
Olsson, J
Hahn, RG
机构
[1] Cent Hosp, Dept Anaesthesia & Intens Care, Sundsvallt, Sweden
[2] Soder Hosp, Karolinska Inst, Stockholm, Sweden
关键词
toxicity; glycine; pharmacology; monitoring; electrocardiography; complications; hyponatraemia; mouse;
D O I
10.1093/bja/82.2.250
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Glycine 1.5% is the most widely used irrigating fluid during endoscopic procedures. To investigate if glycine toxicity is a mechanism promoting a fatal outcome when the solution is absorbed, we administered glycine 200 or 300 ml kg(-1) dissolved in sterile water or normal saline, and also normal saline alone, over 60 min by i.v. infusion to 100 mice under methoxyflurane anaesthesia. Survival rates were 29% after 1.5% glycine, 21% after 1.5% glycine in normal saline, 67% after normal saline and 100% in controls. Both solutions containing glycine induced bradycardia and prolongation of the PQ interval and QRS duration, while only 1.5% glycine increased the water content of the myocardium. These results suggest that glycine promotes bradycardia and death, regardless of whether hyponatraemia or hypo-osmolality is present. We conclude that glycine toxicity is an important factor that increases the risk of administration of an irrigating fluid.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [31] Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes
    Davis, JL
    Gardner, SY
    Jones, SL
    Schwabenton, BA
    Papich, MG
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (02) : 99 - 104
  • [32] PHARMACOLOGY AND TOXICITY OF HIGH-DOSE CYTARABINE BY 72-HOUR CONTINUOUS INFUSION
    DONEHOWER, RC
    KARP, JE
    BURKE, PJ
    CANCER TREATMENT REPORTS, 1986, 70 (09): : 1059 - 1065
  • [33] EVALUATION OF 24-HOUR INFUSION OF HIGH-DOSE METHOTREXATE - PHARMACOKINETICS AND TOXICITY
    GOH, TS
    WONG, KY
    LAMPKIN, B
    OLEARY, J
    GNARRA, D
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 3 (03) : 177 - 180
  • [34] Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT
    F K Główka
    M Karaźniewicz-łada
    G Grund
    T Wróbel
    J Wachowiak
    Bone Marrow Transplantation, 2008, 42 : S67 - S70
  • [35] Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours
    Sastre, J
    PazAres, L
    DiazRubio, E
    CortesFunes, H
    Carcas, A
    Gruia, G
    Herait, P
    FdzChacon, C
    Martin, C
    Farr, I
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1141 - 1141
  • [36] Transcriptional response in normal mouse tissues after i.v. 211At administration - response related to absorbed dose, dose rate, and time
    Britta Langen
    Nils Rudqvist
    Toshima Z Parris
    Emil Schüler
    Johan Spetz
    Khalil Helou
    Eva Forssell-Aronsson
    EJNMMI Research, 5
  • [37] High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans
    Barry V. O’Neill
    Rodney J. Croft
    Sumie Leung
    Chris Oliver
    K. Luan Phan
    Pradeep J. Nathan
    Psychopharmacology, 2007, 195 : 85 - 93
  • [38] High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans
    O'Neill, Barry V.
    Croft, Rodney J.
    Leung, Sumie
    Oliver, Chris
    Phan, K. Luan
    Nathan, Pradeep J.
    PSYCHOPHARMACOLOGY, 2007, 195 (01) : 85 - 93
  • [39] Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome
    Maesawa, Yoko
    Deguchi, Masashi
    Tanimura, Kenji
    Morizane, Mayumi
    Ebina, Yasuhiko
    Yamada, Hideto
    REPRODUCTIVE MEDICINE AND BIOLOGY, 2018, 17 (02) : 149 - 154
  • [40] Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT
    Glowka, F. K.
    Karazniewicz-Lada, M.
    Grund, G.
    Wrobel, T.
    Wachowiak, J.
    BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 2) : S67 - S70